FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Kelley John P   2. Issuer Name and Ticker or Trading Symbol MEDICINES CO /DE [MDCO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President and COO (Last) (First) (Middle) THE MEDICINES COMPANY, 8 CAMPUS DRIVE 3. Date of Earliest Transaction (Month/Day/Year) 01/03/2007 (Street) PARSIPPANY, NJ 07054 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 01/03/2007   M   25,000 A $ 18.27 0 D   Common Stock (1) 01/03/2007   S   25,000 D $ 31.98 0 D   Common Stock 01/03/2007   M   25,000 A $ 18.27 0 D   Common Stock (1) 01/03/2007   S   25,000 D $ 31.83 0 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (right to buy)

$ 18.27

01/03/2007

M

25,000

01/03/2007(2)

11/30/2015

Common Stock

25,000

$ 0

15,625

D

Stock Option (right to buy)

$ 18.27

01/03/2007

M

25,000

01/03/2007(3)

11/30/2015

Common Stock

25,000

$ 0

87,500

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Kelley John P THE MEDICINES COMPANY 8 CAMPUS DRIVE PARSIPPANY, NJ 07054	X		President and COO

Signatures

/s/ John P. Kelley		01/05/2007
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The common stock sales reported on this Form 4 were affected purusant to a Rule 10b5-1 program adopted by Mr. Kelley on November 30, 2006.
(2)	As of January 3, 2007, the original grant (150,000 shares granted on 11/30/05) was vested with respect to 40,625 of the shares covered thereby. The remaining 109,375 of the shares covered by the option vest in equal monthly installments ending on 11/30/09.
(3)	As of January 3, 2007, the original grant (112,500 shares granted on 11/30/05) was fully vested. After the exercise of the options reported hereby, as of January 3, 2007, 87,500 of the shares covered by the option were vested but not exercised and are subject to the terms of the lock-up agreement between Mr. Kelley and The Medicines Company (the "Lock-Up")under which Mr. Kelley has agreed not to sell, transfer, pledge or otherwise dispose of the shares underlying the option, except as set forth in the Lock-Up. The Lock-Up will expire with respect to one-forth-eighth (1/48) of the original number of shares underlying the option on the 30th day of each calendar month, beginning on December 30, 2005. In addition, the Lock-Up will expire if Mr. Kelley ceases to be employed by The Medicines Company for any reason or upon consummation of a "Change of Control Event" as defined in The Medicines Company's 2004 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.